We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed the most recent trading day at $65.61, moving -0.56% from the previous trading session. This change was narrower than the S&P 500's 1.1% loss on the day. Meanwhile, the Dow lost 1.19%, and the Nasdaq, a tech-heavy index, lost 3.27%.
Prior to today's trading, shares of the pharmaceutical had lost 2.9% over the past month. This has lagged the Medical sector's loss of 2.4% and was narrower than the S&P 500's loss of 3.02% in that time.
Investors will be hoping for strength from Astrazeneca as it approaches its next earnings release. On that day, Astrazeneca is projected to report earnings of $0.84 per share, which would represent a year-over-year decline of 11.58%. Meanwhile, our latest consensus estimate is calling for revenue of $11.34 billion, down 0.44% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.61 per share and revenue of $46.35 billion, which would represent changes of +8.41% and +4.51%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Astrazeneca is currently a Zacks Rank #3 (Hold).
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 18.28. Its industry sports an average Forward P/E of 13.76, so we one might conclude that Astrazeneca is trading at a premium comparatively.
Meanwhile, AZN's PEG ratio is currently 1.21. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.61 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 154, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know
Astrazeneca (AZN - Free Report) closed the most recent trading day at $65.61, moving -0.56% from the previous trading session. This change was narrower than the S&P 500's 1.1% loss on the day. Meanwhile, the Dow lost 1.19%, and the Nasdaq, a tech-heavy index, lost 3.27%.
Prior to today's trading, shares of the pharmaceutical had lost 2.9% over the past month. This has lagged the Medical sector's loss of 2.4% and was narrower than the S&P 500's loss of 3.02% in that time.
Investors will be hoping for strength from Astrazeneca as it approaches its next earnings release. On that day, Astrazeneca is projected to report earnings of $0.84 per share, which would represent a year-over-year decline of 11.58%. Meanwhile, our latest consensus estimate is calling for revenue of $11.34 billion, down 0.44% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.61 per share and revenue of $46.35 billion, which would represent changes of +8.41% and +4.51%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Astrazeneca. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Astrazeneca is currently a Zacks Rank #3 (Hold).
Digging into valuation, Astrazeneca currently has a Forward P/E ratio of 18.28. Its industry sports an average Forward P/E of 13.76, so we one might conclude that Astrazeneca is trading at a premium comparatively.
Meanwhile, AZN's PEG ratio is currently 1.21. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 1.61 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 154, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.